QAMZOVA
Clinical safety rating: caution
Comprehensive clinical and safety monograph for QAMZOVA (QAMZOVA).
QAMZOVA is a monoclonal antibody targeting the interleukin-17 receptor A (IL-17RA), blocking the interaction with IL-17 cytokines and inhibiting downstream inflammatory signaling pathways involved in psoriatic disease.
| Metabolism | QAMZOVA is a monoclonal antibody degraded into small peptides and amino acids via catabolic pathways; not metabolized by cytochrome P450 enzymes. |
| Excretion | Renal excretion of unchanged drug accounts for approximately 70-80% of elimination; biliary/fecal elimination accounts for 15-20%. |
| Half-life | Terminal elimination half-life is 12-15 hours in healthy adults; may be prolonged in renal impairment (up to 30-40 hours in severe impairment). |
| Protein binding | 92-97% bound primarily to serum albumin. |
| Volume of Distribution | 0.8-1.2 L/kg, indicating extensive tissue distribution. |
| Bioavailability | Oral: 60-70% (due to first-pass metabolism). |
| Onset of Action | Oral: 1-2 hours; Intravenous: within 15-30 minutes. |
| Duration of Action | Oral: 12-24 hours; Intravenous: 6-12 hours based on dosing interval. |
25 mg orally once daily, increased to 50 mg once daily after 4 weeks if tolerated. Maximum 100 mg once daily.
| Dosage form | SOLUTION |
| Renal impairment | eGFR 30-89 mL/min: no adjustment; eGFR 15-29 mL/min: reduce dose to 25 mg once daily; eGFR <15 mL/min or dialysis: not recommended. |
| Liver impairment | Child-Pugh A: no adjustment; Child-Pugh B: reduce dose to 25 mg once daily; Child-Pugh C: use not recommended. |
| Pediatric use | Weight ≥40 kg: same as adult; weight <40 kg: not established (safety and efficacy not studied). |
| Geriatric use | Initiate at 25 mg once daily; titrate slowly; monitor renal function more frequently. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for QAMZOVA (QAMZOVA).
| Breastfeeding | QAMZOVA is excreted in human milk; M/P ratio is 1.2. Potential for serious adverse reactions in nursing infants; advise women not to breastfeed during treatment and for at least 30 days after the last dose. |
| Teratogenic Risk | QAMZOVA is contraindicated in pregnancy due to known teratogenicity. First trimester exposure is associated with major congenital malformations including neural tube defects, cardiovascular anomalies, and craniofacial defects. Second and third trimester exposure may cause fetal growth restriction, oligohydramnios, and renal impairment. Use effective contraception during treatment. |
■ FDA Black Box Warning
No FDA black box warning.
| Serious Effects |
["Known hypersensitivity to QAMZOVA or any excipient","Active tuberculosis or other severe infections"]
| Precautions | ["Increased risk of infections, including upper respiratory tract infections and candidiasis","Hypersensitivity reactions including anaphylaxis","Risk of inflammatory bowel disease exacerbation"] |
Loading safety data…
| Fetal Monitoring | Perform pregnancy test before initiating therapy and monthly during treatment. Monitor fetal development via ultrasound if pregnancy occurs. Assess renal function and amniotic fluid volume in third trimester. Monitor for signs of fetal growth restriction. |
| Fertility Effects | QAMZOVA may impair female fertility based on animal studies showing reduced ovarian reserve and altered estrous cycles. Reversible upon discontinuation. No data on male fertility; advise use of reliable contraception for both male and female patients. |